‹ News
SYRE LASR ANRO DELL CIEN BCRX DSGN CAVA GTE XRPC

ANRO: Ascending Triangle detected on 17 Mar 2026

Overall Score
88 of 100
Strong
Win Probability
75%
High
Reward / Risk
2.2 : 1
$0.50 reward $-0.23 risk
Current Setup
Alto reported full-year 2025 results on March 16, 2026, catalyzing a strong technical setup. ANRO has formed an ascending triangle from consolidation, with the current price at $24.29 sitting just above key resistance at $23.95 and well above support at $20.46. The structure score of 15.0/15 reflects textbook triangle geometry. Volume is exceptional at 792,466 shares (3.14x average), providing strong breakout confirmation. Breakout score of 13.0/13 indicates imminent upside potential. Overall score of 87.6/98 signals high-quality pattern with 74.57% win probability. RSI at 68.08 is elevated but not yet overbought.
Stock Context
Alto announced a $120 million private placement financing on March 16, 2026, led by Commodore Capital with participation from new and existing biotech investors. After giving effect to the net proceeds, the company estimates cash and cash equivalents would have been approximately $275 million as of February 28, 2026. ALTO-207 Phase 2b initiation is expected in H1 2026 and ALTO-101 topline data is expected around end of Q1 2026. BTIG Research lifted price target to $28.00 with buy rating on February 17, and Chardan Capital boosted target to $30.00 with buy rating on January 5. Six analysts rate Buy, one Hold, one Sell. The financing and institutional backing validate pipeline strategy.
What to Expect
An ascending triangle breakout above $23.95 resistance, with conservative target at $25.51 (+5.1% from current), is supported by the 74.57% win probability. Historical data suggests measured moves could extend toward $28-30 based on analyst price targets and pattern geometry. Volume needs to sustain above 250k-300k daily average for confirmation. Invalidation occurs at support breakdown below $20.46, which would negate the bullish structure. RSI expansion beyond 75 would signal strength; failure to close above resistance on this attempt indicates triangle failure.
Risk Factors
Sell-side analysts predict full-year 2026 EPS of -2.54, underscoring ongoing cash burn despite extended runway. ALTO-101 Phase 2 data expected end of Q1 2026 — trial failure would trigger sharp selloff. Weiss Ratings maintains sell (e+) rating as of December 29. Beta of 1.34 creates amplified downside on sector weakness. Volatility at 97.1% is elevated; 47.75% one-month gain creates technical exhaustion risk. Pattern is post-catalyst (financing announcement), so momentum may fade if Phase 2b or Phase 3 initiation delays materialize. Dilution from PIPE shares could pressure post-breakout momentum.
Sources: Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights · Alto Neuroscience, Inc. - Alto Neuroscience Announces $120 Million Private Placement Financing · Alto Neuroscience at Stifel 2026 Virtual CNS Forum | ANRO Stock News · Alto Neuroscience raises $120M in private placement | ANRO SEC Filing - Form 8-K · ANRO - Alto Neuroscienc Latest Stock News & Market Updates · Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 (NYSE:ANRO) | Seeking Alpha · Alto Neuroscience Secures $120 Million Private Placement Financing - TipRanks.com · Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights | Morningstar · Alto Neuroscience Announces $120 Million Private Placement Financing · Alto Neuroscience (NYSE:ANRO) Sets New 1-Year High – Here’s Why - Markets Daily · Alto Neuroscience, Inc. (ANRO) Stock Price, News, Quote & History - Yahoo Finance · ANRO - Alto Neuroscienc Latest Stock News & Market Updates · Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights | Morningstar · Alto Neuroscience (ANRO) Stock Price, News & Analysis $ANRO · Alto Neuroscience (NYSE:ANRO) Sets New 1-Year High – Here’s Why - Markets Daily · Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights · Alto Neuroscience, Inc. (ANRO) Earnings Dates & Report | Seeking Alpha · Alto Neuroscience, Inc. - Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights · Alto Neuroscience Earnings Dates, Reports, Calls 2016-2026 (NYSE: ANRO) | WallStreetZen · Alto Neuroscience details precision psychiatry pipeline | ANRO SEC Filing - Form 10-K
Market & Sector Regime
Market
Neutral -0.18
-1.0 0 +1.0
Health Care Sector
Neutral -0.18
-1.0 0 +1.0
Other Patterns Detected Today
Bull Flag
65 days in pattern
Weak 25.2
Overall Score
38 of 40
Exceptional
Pattern Quality
20 of 20
Exceptional
Setup
13 of 20
Moderate
R/R
17 of 18
Exceptional
Context
Pattern Quality Score
15 of 15
Exceptional
Structure
13 of 13
Exceptional
Breakout
10 of 12
Strong
Volume
Recent Performance
+10.5%
1W
+17.7%
2W
+47.8%
1M
+65.5%
3M
Momentum & Trend
RSI (14)
68.1
Neutral
MACD Histogram
+0.25
Bullish
Bollinger Band Position
105.7%
Upper Band
Volatility & Risk
20-Day Volatility
0.97
Very High
ATR %
7.7%
High
Beta
1.34
Above Mkt
Volume Analysis
Volume Ratio
3.14x
Very High
20-Day Avg Vol
252K
shares / day
Current Volume
792K
shares traded
Price Levels
Target
$25.51
52W High
$25.12
Current
$24.29
Resistance
$23.95
Stop Loss
$22.08
Support
$20.46
52W Low
$1.60
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.